Novogen Ltd (NVGN) 7.40 $NVGN
Premarket Gainers / Losers as of 9:15 am
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 8:15AM CDT
BRCM: 46.18 (+2.20), CSLT: 7.85 (+0.36), NVGN: 7.40 (-0.30), ASML: 107.81 (+10.06), VICL: 1.01 (-0.02), NRP: 5.54 (-1.38), ENZN: 1.70 (+0.20), GBSN: 4.98 (+1.44), LOOK: 1.75 (-0.51), ONVO: 5.14 (+0.67), CMG: 641.23 (-51.29), ANGI: 6.46 (+0.31), PKT: 11.42 (+1.91)
Cantrixil Receives Orphan Drug Designation from FDA
PR Newswire - Tue Apr 21, 9:27PM CDT
US-Australian drug discovery company, Novogen, today announced that its subsidiary joint venture company with Yale University, CanTx, Inc, has today received notification from the U.S. Food and Drug Administration (FDA) that its chemotherapy candidate drug, Cantrixil, has been granted Orphan Drug Designation for ovarian cancer.
NVGN: 7.40 (-0.30)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 11:47AM CDT
RNO: 1.95 (-0.12), ECHO: 33.39 (+1.37), LJPC: 23.04 (+1.22), CEA: 45.82 (-0.73), NVGN: 7.40 (-0.30), NHLD: 3.80 (-0.20), VLTC: 15.14 (-1.04), GEVO: 2.79 (+0.78), BIOD: 1.24 (-0.01), PRTO: 12.15 (-0.08), TTS: 14.52 (-0.33), ENZN: 1.70 (+0.20), AST: 13.61 (-0.11), VGGL: 2.77 (+0.27), GLF: 13.77 (-0.11), NVTA: 12.76 (-1.12), FTK: 15.56 (+0.10), PGN: 1.82 (+0.06), UCTT: 5.66 (+0.14), SANM: 21.09 (+0.40)
Novogen (NVGN) Stock Falls Today on Private Placement
at The Street - Tue Apr 21, 10:52AM CDT
Shares of Novogen (NVGN) were down in late morning trading Monday after the Australian and U.S. biotechnology company announced it had conducted a private placement and offered rights to shareholders.
NVGN: 7.40 (-0.30)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 8:22AM CDT
HOG: 56.23 (+0.51), TNXP: 6.73 (+0.21), ALNY: 118.00 (-2.70), LRE: 8.43 (+0.08), LRCX: 78.36 (+0.52), MYL: 72.40 (-1.67), NVGN: 7.40 (-0.30), BIOC: 3.15 (+0.02), NBG: 1.19 (+0.12), VLTC: 15.14 (-1.04), FTNT: 38.07 (-0.01), BCLI: 4.29 (-0.09), SANM: 21.09 (+0.40)
Profit taking on deck for Novogen today; capital raise announced
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 7:02AM CDT
NVGN: 7.40 (-0.30)
Novogen Conducts Private Placement and Announces Rights Offering to Shareholders
PR Newswire - Tue Apr 21, 6:00AM CDT
Novogen Limited (ASX:NRT; NASDAQ:NVGN) ("Company" or "Novogen"
, an Australian/US biotechnology company, advises that it has entered into definitive agreements today to issue approximately 51 million fully-paid ordinary shares plus one attaching 6-month option and half of one attaching 5-year option for every ordinary share issued, to institutional investors in the United States in a private placement for aggregate gross proceeds of approximately AU$15,500,000 ("Placement" . The closing of the Placement is expected to occur on or about 24 April 2015 and is subject to satisfaction of customary closing conditions. The issue of the attaching options under the Placement is subject to shareholder approval.
NVGN: 7.40 (-0.30)
Novogen up on cancer drug candidate pre-clinical data
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 12:38PM CDT
NVGN: 7.40 (-0.30)
Cantrixil Highly Successful in Preventing Growth of Chemo-Resistant Ovarian Cancer
PR Newswire - Mon Apr 20, 8:00AM CDT
US-Australian drug discovery company, Novogen Ltd, (ASX:NRT; NASDAQ:NVGN), its subsidiary, CanTx, Inc, and Yale University today disclosed key pre-clinical data on experimental anti-cancer drug, Cantrixil, justifying the optimism in the ability of this drug candidate to significantly improve the survival outlook for patients with ovarian cancer. The data was presented by Professor Gil Mor of Yale Medical School to the American Association for Cancer Research (AACR) Annual Meeting.
NVGN: 7.40 (-0.30)
Novogen (NVGN) Stock Rises Today After Announcing Brain Cancer Treatment Collaboration
at The Street - Fri Apr 17, 2:12PM CDT
Shares of Novogen (NVGN) were up Friday after the company announced an MOU with the Feinstein Institute for Medical Research of New York to collaborate on brain cancer treatments.
NVGN: 7.40 (-0.30)
Novogen up 14% premarket on collaboration with Feinstein Institute in brain cancer
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 7:46AM CDT
NVGN: 7.40 (-0.30)
Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer
PR Newswire - Fri Apr 17, 6:00AM CDT
US-Australian drug discovery company, Novogen, today announced that it had signed a Memorandum of Understanding with the Feinstein Institute for Medical Research ('Feinstein Institute' of New York to collaborate with the objective of developing effective treatments for brain cancers.
NVGN: 7.40 (-0.30)
BUYINS.NET: NVGN, VGSH, DXJS, Have Remained On Naked Short Lists 13 Consecutive Days
M2 - Tue Apr 14, 10:29AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Has Remained On the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Novogen Ltd (NASDAQ:NVGN), Vanguard Short Term Government Bond ETF (NASDAQ:VGSH), (NASDAQ
XJS). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
NVGN: 7.40 (-0.30), DXJS: 35.22 (+0.25), VGSH: 61.10 (-0.04)
Premarket Gainers / Losers as of 9:15 am
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 8:15AM CDT
BRCM: 46.18 (+2.20), CSLT: 7.85 (+0.36), NVGN: 7.40 (-0.30), ASML: 107.81 (+10.06), VICL: 1.01 (-0.02), NRP: 5.54 (-1.38), ENZN: 1.70 (+0.20), GBSN: 4.98 (+1.44), LOOK: 1.75 (-0.51), ONVO: 5.14 (+0.67), CMG: 641.23 (-51.29), ANGI: 6.46 (+0.31), PKT: 11.42 (+1.91)
Cantrixil Receives Orphan Drug Designation from FDA
PR Newswire - Tue Apr 21, 9:27PM CDT
US-Australian drug discovery company, Novogen, today announced that its subsidiary joint venture company with Yale University, CanTx, Inc, has today received notification from the U.S. Food and Drug Administration (FDA) that its chemotherapy candidate drug, Cantrixil, has been granted Orphan Drug Designation for ovarian cancer.
NVGN: 7.40 (-0.30)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 11:47AM CDT
RNO: 1.95 (-0.12), ECHO: 33.39 (+1.37), LJPC: 23.04 (+1.22), CEA: 45.82 (-0.73), NVGN: 7.40 (-0.30), NHLD: 3.80 (-0.20), VLTC: 15.14 (-1.04), GEVO: 2.79 (+0.78), BIOD: 1.24 (-0.01), PRTO: 12.15 (-0.08), TTS: 14.52 (-0.33), ENZN: 1.70 (+0.20), AST: 13.61 (-0.11), VGGL: 2.77 (+0.27), GLF: 13.77 (-0.11), NVTA: 12.76 (-1.12), FTK: 15.56 (+0.10), PGN: 1.82 (+0.06), UCTT: 5.66 (+0.14), SANM: 21.09 (+0.40)
Novogen (NVGN) Stock Falls Today on Private Placement
at The Street - Tue Apr 21, 10:52AM CDT
Shares of Novogen (NVGN) were down in late morning trading Monday after the Australian and U.S. biotechnology company announced it had conducted a private placement and offered rights to shareholders.
NVGN: 7.40 (-0.30)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 8:22AM CDT
HOG: 56.23 (+0.51), TNXP: 6.73 (+0.21), ALNY: 118.00 (-2.70), LRE: 8.43 (+0.08), LRCX: 78.36 (+0.52), MYL: 72.40 (-1.67), NVGN: 7.40 (-0.30), BIOC: 3.15 (+0.02), NBG: 1.19 (+0.12), VLTC: 15.14 (-1.04), FTNT: 38.07 (-0.01), BCLI: 4.29 (-0.09), SANM: 21.09 (+0.40)
Profit taking on deck for Novogen today; capital raise announced
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 7:02AM CDT
NVGN: 7.40 (-0.30)
Novogen Conducts Private Placement and Announces Rights Offering to Shareholders
PR Newswire - Tue Apr 21, 6:00AM CDT
Novogen Limited (ASX:NRT; NASDAQ:NVGN) ("Company" or "Novogen"
, an Australian/US biotechnology company, advises that it has entered into definitive agreements today to issue approximately 51 million fully-paid ordinary shares plus one attaching 6-month option and half of one attaching 5-year option for every ordinary share issued, to institutional investors in the United States in a private placement for aggregate gross proceeds of approximately AU$15,500,000 ("Placement" . The closing of the Placement is expected to occur on or about 24 April 2015 and is subject to satisfaction of customary closing conditions. The issue of the attaching options under the Placement is subject to shareholder approval. NVGN: 7.40 (-0.30)
Novogen up on cancer drug candidate pre-clinical data
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 12:38PM CDT
NVGN: 7.40 (-0.30)
Cantrixil Highly Successful in Preventing Growth of Chemo-Resistant Ovarian Cancer
PR Newswire - Mon Apr 20, 8:00AM CDT
US-Australian drug discovery company, Novogen Ltd, (ASX:NRT; NASDAQ:NVGN), its subsidiary, CanTx, Inc, and Yale University today disclosed key pre-clinical data on experimental anti-cancer drug, Cantrixil, justifying the optimism in the ability of this drug candidate to significantly improve the survival outlook for patients with ovarian cancer. The data was presented by Professor Gil Mor of Yale Medical School to the American Association for Cancer Research (AACR) Annual Meeting.
NVGN: 7.40 (-0.30)
Novogen (NVGN) Stock Rises Today After Announcing Brain Cancer Treatment Collaboration
at The Street - Fri Apr 17, 2:12PM CDT
Shares of Novogen (NVGN) were up Friday after the company announced an MOU with the Feinstein Institute for Medical Research of New York to collaborate on brain cancer treatments.
NVGN: 7.40 (-0.30)
Novogen up 14% premarket on collaboration with Feinstein Institute in brain cancer
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 7:46AM CDT
NVGN: 7.40 (-0.30)
Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer
PR Newswire - Fri Apr 17, 6:00AM CDT
US-Australian drug discovery company, Novogen, today announced that it had signed a Memorandum of Understanding with the Feinstein Institute for Medical Research ('Feinstein Institute'
of New York to collaborate with the objective of developing effective treatments for brain cancers. NVGN: 7.40 (-0.30)
BUYINS.NET: NVGN, VGSH, DXJS, Have Remained On Naked Short Lists 13 Consecutive Days
M2 - Tue Apr 14, 10:29AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Has Remained On the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Novogen Ltd (NASDAQ:NVGN), Vanguard Short Term Government Bond ETF (NASDAQ:VGSH), (NASDAQ
XJS). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net . NVGN: 7.40 (-0.30), DXJS: 35.22 (+0.25), VGSH: 61.10 (-0.04)
